Yu Liang
About
In The Last Decade
Yu Liang
28 papers receiving 4.3k citations
Hit Papers
Peers
Comparison fields: 5 of 124
- Molecular Biology 3.5k
- Cancer Research 3.4k
- Oncology 342
- Immunology 227
- Pulmonary and Respiratory Medicine 152
Countries citing papers authored by Yu Liang
This map shows the geographic impact of Yu Liang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yu Liang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yu Liang more than expected).
Fields of papers citing papers by Yu Liang
This network shows the impact of papers produced by Yu Liang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yu Liang. The network helps show where Yu Liang may publish in the future.
Co-authorship network of co-authors of Yu Liang
This figure shows the co-authorship network connecting the top 25 collaborators of Yu Liang. A scholar is included among the top collaborators of Yu Liang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yu Liang. Yu Liang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 1 | |
| 3 | 6 | |
| 4 | 15 | |
| 5 | 11 | |
| 6 | 5 | |
| 7 | 5 | |
| 8 | 3 | |
| 9 | 252 | |
| 10 | 22 | |
| 11 | 1 | |
| 12 | 23 | |
| 13 | 13 | |
| 14 | 1 | |
| 15 | 42 | |
| 16 | 12 | |
| 17 | 43 | |
| 18 | Characterization of MicroRNA Expression Levels and Their Biological Correlates in Human Cancer Cell Lines breakdown → | 586 |
| 19 | A microRNA component of the p53 tumour suppressor network breakdown → | 2177 |
| 20 | Intravesical immunotoxin as adjuvant therapy to prevent the recurrence of bladder cancer. | 8 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.